Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JBH492
- Development stage
- Discontinued
- Lead developer
- Novartis
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
JBH492 is an investigational antibody-drug conjugate (ADC) developed by Novartis. It consists of a humanized IgG1 monoclonal antibody targeting the CC chemokine receptor 7 (CCR7), which is overexpressed in certain hematologic malignancies. The antibody is conjugated via a cleavable linker to the cytotoxic maytansinoid DM4 (ravtansine). Upon binding to CCR7 on cancer cells, JBH492 is internalized and trafficked to lysosomes where the DM4 payload is released, inhibiting tubulin polymerization and inducing cell death through mitotic arrest. The drug was primarily developed for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma[1][2][3][4][8].
- Other names
- anti-CCR7 antibody-drug conjugateanti-CCR-7 antibody-drug conjugateanti-CCR 7 antibody-drug conjugateAnti-CCR7 antibody-drug conjugate - Novartis PharmaceuticalsAnti-CCR-7 antibody-drug conjugate - Novartis PharmaceuticalsAnti-CCR 7 antibody-drug conjugate - Novartis Pharmaceuticals
02
Targets
CCR7 (C-C Motif Chemokine Receptor 7)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on JBH492.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JBH492.